We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.30 | -1.09% | 27.25 | 27.00 | 27.50 | 27.50 | 27.00 | 27.50 | 102,744 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 66.64M | -10.1M | -0.0222 | -12.16 | 122.83M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/5/2021 19:25 | wanttowin/faz - I assume they are either smoke signals or somemone trying to boost the deal count. | boadicea | |
04/5/2021 17:31 | Thanks faz, but surely too many of them to be buy/sell checks ? | wanttowin | |
04/5/2021 16:24 | In Part: "Trellus Health Announces Experienced Leaders to Drive Next Phase of Growth Press Releases | May 03, 2021 Industry veterans from Teladoc Health, Talkspace, Harwood Capital and Polar Capital join executive team and board of directors White Plains, May 3, 2021: Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its executive team and board of directors. The company named Alex Kozersky as Chief Sales Officer, Bob Birdsong as Chief Marketing Officer and Carole Romasco as Vice President of Product Management. Jaime King was promoted to Vice President of Compliance, Operations, and Human Resources." | mirandaj | |
04/5/2021 15:27 | wantowin- I've seen them ever seen trading volumes became available on the internet. I would imagine they are not trades as dealing costs would be more than the share so maybe market makers checking buy/sell prices. Happy to be corrected. | faz | |
04/5/2021 14:53 | I've added again, this has to be bargain territory imo. | wanttowin | |
04/5/2021 14:43 | Can anyone tell me what all these tiny trades are ?? Lot and lots of 1,2,3,4,5,6, trades ? | wanttowin | |
04/5/2021 14:08 | Certamente :) | tongosti | |
04/5/2021 14:07 | I think the forecasts for EKF have been woeful(in a positive way this year on numerous times). No fault of EKF but given CV19 and a conservative approach by the business they underpromise and over delivery. Last word from me, is from the last results: Whilst necessarily maintaining a conservative approach to forecasting for our core business, we have already announced that our performance for the first quarter of 2021 will be materially ahead of expectations and the same quarter last year. This morning's news that we have expanded a key supply agreement to become a multi-million dollar global supply contract, means that we are confident that trading for the year ending 31 December 2021 will be significantly ahead of already upgraded expectations." | mysteronz | |
04/5/2021 14:05 | Tong, I think you'll find that you mean "two." I use Sharescope and their numbers are not always accurate. CD | cambridgedon | |
04/5/2021 13:54 | You too make me laugh. Didn't I say sharescope?Go check it out and then you will probably understand why you find yourselves in this predicament. Ps. Share price heading down despite daily ramping posts. | tongosti | |
04/5/2021 12:54 | Crossed in the ether! CD | cambridgedon | |
04/5/2021 12:43 | Can you remind us where the £47.4 comes from. It certainly seems a big fall following FY21 which was upgraded at the T/U "Board confident that trading for Y/E Dec21 will be significantly ahead of already upgraded management expectations." Thanks CD | cambridgedon | |
04/5/2021 12:37 | Tongosti...No one wants to engage with you, because what you want to discuss is either irrelevant or incorrect/out of date/ and backward looking. But I feel it should at least be pointed out that based on the most recent trading update, which I believe is conservative, that N-1 Singer analyst Chris Glasper has upgraded his forecast for December 2021 revenues to £64 million and adjusted pre-tax profit to £15.5 million. Effectively demonstrating that you are out of date and irrelevant. Don't bother trying to extend the conversation, it's already over! EKF's CEO stated the PBS was ramping in a very big way, so let's see what the effects from the private sector partner (believed to be Amazon) does in terms of the full year, and importantly beyond. | wan | |
04/5/2021 12:15 | Wan - while you're at it please help us understand why the city's 2022 revenue estimate of only £47m is not a disappointment? Ta. Amazed (!) no one here likes to touch the subject. PS. Please avoid cliches along the lines of "...you're looking at it way beyond 2020". | tongosti | |
04/5/2021 12:13 | CD...Lumira is not competing with EKF. I keep an eye on LumiraDx purely out of interest and the past Ron Zwanziger connection with EKF (not to mention Alere etc), his departure from EKF was apparently due to the arrival of Chris Mills. But I am far more interested in the current managements ambitions and subsequently the multiple opportunities presenting to EKF, including those via MyHealthChecked. | wan | |
04/5/2021 11:44 | Wan, Thanks for this. Clearly this is a hot space at present; however, to what extent is LumiraDx competing with EKF? Also, having kept all my EKF, added to RENX and VRCI free shares and awaiting Trellus I find that I now have a very hefty weighting of healthcare-type exposure ( no complaints, I've made a lot) but unsure whether I need to add any more. What was the attraction of Lumira? Was it the Ron Z connection or something else which you spotted? Best, CD | cambridgedon | |
04/5/2021 07:51 | Pugugly...Indeed, and likewise I am very optimistic about the prospects for EKF's Life Science division, as is indeed CEO Julian Baines, stating in Hastings update article that EKF is now seriously transitioning from a medium sized enzyme manufacturer to a large one in order to scale up and capture all those opportunities that are now presenting themselves. Of course, life science is just one division of EKF, which importantly is also developing and supplying critical elements to diagnostic companies (including EKF's diagnostic division itself). And diagnostics itself has entered a major growth phase - Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions BY ANITA CHAKRAVERTY 20/04/2021 “The perception used to be that diagnostics tended to carry similar development risk to a drug without the potential return of similarly large addressable markets. That perception has changed over the course of the past year,” Gaugler said. The coronavirus pandemic has undoubtedly had a radical impact on the diagnostics field. Several diagnostics companies have benefited enormously from swiftly steering their business models to deal with the surge in testing. Gaugler predicted there would be increasing interest in emerging diagnostic applications, with the diagnostics market expected to grow massively over the next decade. Full story - For a number of reasons I have been keeping tabs on one company in the above article, LumiraDx, Chief Executive Officer Ron Zwanziger. LumiraDx is a good example, among many, of the huge growth prospects for diagnostics. LumiraDx is a point of care diagnostics testing company which has announced a $5 billion merger with a special purpose acquisition corporation and has doubled its footprint at the Maxim Park office complex in Lanarkshire, Scotland. | wan | |
02/5/2021 19:07 | In a major growth sector Pays your money - only time will tell if a better choice. | pugugly | |
02/5/2021 18:44 | sharw:- Suggest you copy your post to the Nomad - | pugugly | |
02/5/2021 18:01 | Honestly it's mind boggling the ignorance of most. Never mind that the share price never topped the 80p for months after I warned folks. It also doesn't matter to them that 2022 forecast revenue (£47m according to sharescope) are about 20% lower than what the market are expecting this fiscal year. Any wonder the director sold and the share price had stalled for ages?Wan - are you posting tomorrow or you will skip it due to bank holiday? Ta. | tongosti | |
01/5/2021 14:31 | The sale of shares by a director caused me to look him up on the Investors section of the EKF website. Here is what it says: Adam Reynolds, Non-Executive Director Adam is a former stockbroker specialising in corporate finance. He has built, rescued and re-financed a number of public companies. He is currently Chairman of Autoclenz Group Limited, Orogen Gold plc, and Hubco Investments plc and a Director of OptiBiotix Health plc, Premaitha Health plc, and Verdes Management plc. Hubco Investments changed its name to Big Sofa Technologies Group plc in 2016 and he resigned from the board in June 2018. Orogen Gold became a cash shell and Sosandar PLC reversed into it in 2017 at which point he ceased to be Chairman but remained on the Board. Verdes Management changed name to React in 2015 and he resigned at that time. Premaitha Health changed name to Yourgene Health in 2018. OptiBiotix Health resigned 2017 I find it somewhat disturbing that the website is so appallingly maintained. What else on it can we believe? | sharw | |
01/5/2021 12:10 | Exactly. He is just a troll. That is what it boils down to. He doesn’t deserve any response except for being called out as a troll. Tong the troll. Call it what it is. | jsredbird | |
01/5/2021 10:12 | I see that the troll has returned. Why do some posters here continue to feed him. You are just giving him the attention that he desperately craves and also prompting him to wreck this thread with his nonsense. Either just ignore or filter him ! | masurenguy | |
01/5/2021 09:59 | (FAB) Fusion Antibodies is making antibodies for COVID vaccine companies. The stock is tightly held, and valued at 43m. It is fully funded by grants. Do your own research, and I am sure you will all be very impressed. | abeygale |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions